

Substitute for form 1449/PTO				<b><i>Complete if Known</i></b>	
				Application Number	10/567,537-Conf. #9321
				Filing Date	August 9, 2004
				First Named Inventor	Li-Huei Tsai
				Art Unit	1635
				Examiner Name	J. E. Angell
Sheet	1	of	1	Attorney Docket Number	HMV-09001

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
	BA	WO-03/070895	08-28-2003	Ribozyme Pharm Inc et al.	
	BB	WO-02/47466	06-20-2002	Univ Johns Hopkins Med	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	CA	Basi et al., "Antagonistic Effects of β-Site Amyloid Precursor Protein-cleaving Enzymes 1 and 2 on β-Amyloid Peptide Production in Cells," The Journal of Biological Chemistry, 278(34):31512-31520 (2003)			
	CB	Eckert et al., "Elevated Vulnerability to Oxidative Stress-Induced Cell Death and Activation of Caspase-3 by the Swedish Amyloid precursor Protein Mutation," Neurosci Res., 64(2):183-92 (2001) Abstract Only			
	CC	Hussain et al., "Identification of a Novel Aspartic Protease (Asp 2) as Beta-Secretase," Mol. Cell. Neurosci., 14(6):419-427 (1999) Abstract Only			
	CD	Kao et al., "BACE1 Suppression by RNA Interference in Primary Cortical Neurons," The Journal of Biological Chemistry, 279(3):1942-1949 (2004)			
	CE	Li et al., "β-Amyloid Secretases and β-Amyloid Degrading Enzyme Expression In Lens," Molecular Vision, 9:179-83 (2003)			
	CF	Tamagno et al., "Oxidative Stress Increases Expression and Activity of BACE in NT2 Neurons," Neurobiol Dis., 10(3):279-88 (2002) Abstract Only			
	CG	Xia et al., "siRNA-mediated Gene Silencing <i>In Vitro</i> and <i>in vivo</i> ," Nature Biotechnology, 20:1006-1010 (2002)			
	CH	Wood et al., "Ribozymes and siRNA for the Treatment of Diseases of the Nervous System," Molecular Therapeutics 5(4):383-388 (2003)			
Examiner Signature		Date Considered			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.